GSK says RSV jab shows promising response in adults aged 50 to 59
(Alliance News) - GSK PLC on Wednesday said a trial found its respiratory syncytial virus vaccine Arexy delivered an immune response in adults aged 50 to 59.
Read moreMon, 12th Oct 2015 08:16
(Alliance News) - GSK PLC on Wednesday said a trial found its respiratory syncytial virus vaccine Arexy delivered an immune response in adults aged 50 to 59.
Read more(Sharecast News) - Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.
Read more(Alliance News) - GSK PLC on Monday said its monoclonal antibody Jemperli is closer to becoming the first new frontline treatment option in the EU in decades for a certain form of endometrial cancer.
Read more(Alliance News) - The FTSE 100 is likely to open higher on Monday, benefitting from higher oil and gas prices, while fears of escalating regional conflict in the Middle East damp risk sentiment elsewhere.
Read more(Sharecast News) - Pharma giant GSK has announced that European experts recommended the approval of its Jerperli drug for the treatment of a specific type of endometrial cancer - paving the way for marketing authorisation by the continent's regulatory body.
Read more(Sharecast News) - GSK has agreed to settle another lawsuit concerning its discontinued heartburn treatment Zantac, the drugs giant confirmed on Wednesday.
Read more(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:
Read more(Alliance News) - Stock prices in London opened largely higher on Wednesday as market mood remained resilient, despite the continuing conflict in the Middle East, amid a softening of rhetoric from the US central bank.
Read more(Alliance News) - GSK PLC on Wednesday said that it has reached a confidential settlement in the Cantlay/Harper case, which alleged that the firm's heartburn medication can cause cancer.
Read more(Alliance News) - Stocks in London are set to open lower on Wednesday as investor looked ahead to the release of the US Federal Reserve's September meeting minutes later in the day.
Read more(Alliance News) - GSK PLC on Monday said it has reached an exclusive agreement with Chongqing Zhifei Biological Products Ltd to co-promote its shingles vaccine, Shingrix, in China.
Read more(Alliance News) - Stocks in London are set to open higher on Monday as interest rate expectations held steady despite Friday's bumper US nonfarm payrolls report.
Read more(Sharecast News) - GSK has entered into a new exclusive vaccine partnership in China that will extend the availability of its shingle vaccine Shingrix, which will see the UK-listed group generate £2.5bn over the next three years.
Read more(Sharecast News) - Some of Renewi's major shareholders are divided as to whether the recycling company should engage with Australian suitor Macquarie. One major shareholder has told Renewi's board that it should not until Macquarie raised its £636m bid, but another top ten shareholder told The Sunday Times that it should talk to the Australian outfit anyways. Macquarie has until 26 October to make a firm offer. - The Sunday Times
Read more(Sharecast News) - GSK said on Friday that it has sold 270m shares in Haleon - the consumer health business it spun off last year - raising around £885.6m.
Read more